

# Javier Garcia-Castro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1246679/publications.pdf>

Version: 2024-02-01

80  
papers

4,966  
citations

134610

34  
h-index

104191

69  
g-index

83  
all docs

83  
docs citations

83  
times ranked

7472  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer stem cells and clonal evolution in bone sarcomas. , 2022, , 371-391.		0
2	Cellular Heterogeneity and Cooperativity in Glioma Persister Cells Under Temozolomide Treatment. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	0
3	Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients. <i>Veterinary Sciences</i> , 2022, 9, 327.	0.6	5
4	AKT and JUN are differentially activated in mesenchymal stem cells after infection with human and canine oncolytic adenoviruses. <i>Cancer Gene Therapy</i> , 2021, 28, 64-73.	2.2	4
5	The Netrin-1-Neogenin-1 signaling axis controls neuroblastoma cell migration via integrin- $\beta$ 1 and focal adhesion kinase activation. <i>Cell Adhesion and Migration</i> , 2021, 15, 58-73.	1.1	10
6	Humoral responses to SARS-CoV-2 by healthy and sick dogs during the COVID-19 pandemic in Spain. <i>Veterinary Research</i> , 2021, 52, 22.	1.1	16
7	Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma. , 2021, 9, e001703.		16
8	RGB-Marking to Identify Patterns of Selection and Neutral Evolution in Human Osteosarcoma Models. <i>Cancers</i> , 2021, 13, 2003.	1.7	3
9	Systemic Treatment of Immune-Mediated Keratoconjunctivitis Sicca with Allogeneic Stem Cells Improves the Schirmer Tear Test Score in a Canine Spontaneous Model of Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 5981.	1.0	6
10	Sarcoma treatment in the era of molecular medicine. <i>EMBO Molecular Medicine</i> , 2020, 12, e11131.	3.3	154
11	Biodistribution Analysis of Oncolytic Adenoviruses in Canine Patient Necropsy Samples Treated with Cellular Virotherapy. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 525-534.	2.0	2
12	Cellular Virotherapy Increases Tumor-Infiltrating Lymphocytes (TIL) and Decreases their PD-1+ Subsets in Mouse Immunocompetent Models. <i>Cancers</i> , 2020, 12, 1920.	1.7	14
13	First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors. <i>Molecular Therapy</i> , 2020, 28, 1033-1042.	3.7	57
14	SOX2 Expression and Transcriptional Activity Identifies a Subpopulation of Cancer Stem Cells in Sarcoma with Prognostic Implications. <i>Cancers</i> , 2020, 12, 964.	1.7	21
15	The Netrin-4/Laminin $\beta$ 1/Neogenin-1 complex mediates migration in SK-N-SH neuroblastoma cells. <i>Cell Adhesion and Migration</i> , 2019, 13, 33-40.	1.1	8
16	Enhanced Antitumor Efficacy of Oncolytic Adenovirus-Loaded Menstrual Blood-derived Mesenchymal Stem Cells in Combination with Peripheral Blood Mononuclear Cells. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 127-138.	1.9	35
17	Clonal dynamics in osteosarcoma defined by RGB marking. <i>Nature Communications</i> , 2018, 9, 3994.	5.8	40
18	c-Fos induces chondrogenic tumor formation in immortalized human mesenchymal progenitor cells. <i>Scientific Reports</i> , 2018, 8, 15615.	1.6	12

#	ARTICLE	IF	CITATIONS
19	Antitumor virotherapy using syngeneic or allogeneic mesenchymal stem cell carriers induces systemic immune response and intratumoral leukocyte infiltration in mice. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1589-1602.	2.0	21
20	Allogeneic Adipose-Derived Mesenchymal Stem Cells (Horse Allo 20) for the Treatment of Osteoarthritis-Associated Lameness in Horses: Characterization, Safety, and Efficacy of Intra-Articular Treatment. <i>Stem Cells and Development</i> , 2018, 27, 1147-1160.	1.1	27
21	Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy. <i>Cancer Research</i> , 2018, 78, 4891-4901.	0.4	33
22	Role of Activator Protein-1 Complex on the Phenotype of Human Osteosarcomas Generated from Mesenchymal Stem Cells. <i>Stem Cells</i> , 2018, 36, 1487-1500.	1.4	11
23	First-in-child trial of celyvir (autologous mesenchymal stem cells carrying the oncolytic virus) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tj Oncology, 2018, 36, 10543-10543.	0.8	12
24	Engineered LINE-1 retrotransposition in nondividing human neurons. <i>Genome Research</i> , 2017, 27, 335-348.	2.4	128
25	Prospects of Pluripotent and Adult Stem Cells for Rare Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1031, 371-386.	0.8	2
26	Hedgehog Pathway Inhibition Hampers Sphere and Holoclone Formation in Rhabdomyosarcoma. <i>Stem Cells International</i> , 2017, 2017, 1-14.	1.2	10
27	Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus. <i>Stem Cells International</i> , 2017, 2017, 1-10.	1.2	24
28	Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model. <i>Oncotarget</i> , 2017, 8, 45415-45431.	0.8	47
29	Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. <i>Stem Cells International</i> , 2016, 2016, 1-13.	1.2	164
30	Age-associated hydroxymethylation in human bone-marrow mesenchymal stem cells. <i>Journal of Translational Medicine</i> , 2016, 14, 207.	1.8	33
31	Aldh1 Expression and Activity Increase During Tumor Evolution in Sarcoma Cancer Stem Cell Populations. <i>Scientific Reports</i> , 2016, 6, 27878.	1.6	38
32	Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells. <i>Cancer Letters</i> , 2016, 371, 161-170.	3.2	61
33	Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology. <i>Oncolytic Virotherapy</i> , 2015, 4, 149.	6.0	30
34	Mesoporous silica nanoparticles grafted with a light-responsive protein shell for highly cytotoxic antitumoral therapy. <i>Journal of Materials Chemistry B</i> , 2015, 3, 5746-5752.	2.9	73
35	Bone microenvironment signals in osteosarcoma development. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 3097-3113.	2.4	147
36	Mesenchymal stem cells derived from low risk acute lymphoblastic leukemia patients promote NK cell antitumor activity. <i>Cancer Letters</i> , 2015, 363, 156-165.	3.2	15

#	ARTICLE	IF	CITATIONS
37	H3K4me1 marks DNA regions hypomethylated during aging in human stem and differentiated cells. <i>Genome Research</i> , 2015, 25, 27-40.	2.4	119
38	Bone Environment is Essential for Osteosarcoma Development from Transformed Mesenchymal Stem Cells. <i>Stem Cells</i> , 2014, 32, 1136-1148.	1.4	89
39	Mesenchymal stem cells regulate airway contractile tissue remodeling in murine experimental asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 730-740.	2.7	50
40	Dopamine Mobilizes Mesenchymal Progenitor Cells Through D2-Class Receptors and Their PI3K/AKT Pathway. <i>Stem Cells</i> , 2014, 32, 2529-2538.	1.4	8
41	Combination of Single-Photon Emission Computed Tomography and Magnetic Resonance Imaging to Track <sup>111</sup> In-Oxine- <sup>65</sup> Zn Labeled Human Mesenchymal Stem Cells in Neuroblastoma-Bearing Mice. <i>Molecular Imaging</i> , 2014, 13, 7290.2014.00033.	0.7	15
42	Mesenchymal Stromal Cells Derived from the Bone Marrow of Acute Lymphoblastic Leukemia Patients Show Altered BMP4 Production: Correlations with the Course of Disease. <i>PLoS ONE</i> , 2014, 9, e84496.	1.1	39
43	In Vivo Ectopic Implantation Model to Assess Human Mesenchymal Progenitor Cell Potential. <i>Stem Cell Reviews and Reports</i> , 2013, 9, 833-846.	5.6	10
44	A Role for the CXCR3/CXCL10 Axis in Rasmussen Encephalitis. <i>Pediatric Neurology</i> , 2013, 49, 451-457.e1.	1.0	28
45	Enrichment of neural-related genes in human mesenchymal stem cells from neuroblastoma patients. <i>International Journal of Molecular Medicine</i> , 2012, 30, 365-373.	1.8	3
46	Multipotent Mesenchymal Stromal Cells: Clinical Applications and Cancer Modeling. <i>Advances in Experimental Medicine and Biology</i> , 2012, 741, 187-205.	0.8	32
47	Mesenchymal niches of bone marrow in cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 611-616.	1.2	14
48	FUS-CHOP Fusion Protein Expression Coupled to p53 Deficiency Induces Liposarcoma in Mouse but Not in Human Adipose-Derived Mesenchymal Stem/Stromal Cells. <i>Stem Cells</i> , 2011, 29, 179-192.	1.4	57
49	Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. <i>Cancer Gene Therapy</i> , 2010, 17, 476-483.	2.2	126
50	Deficiency in p53 but not Retinoblastoma Induces the Transformation of Mesenchymal Stem Cells <i>In vitro</i> and Initiates Leiomyosarcoma <i>In vivo</i> . <i>Cancer Research</i> , 2010, 70, 4185-4194.	0.4	96
51	Oncolytic virotherapy for neuroblastoma. <i>Discovery Medicine</i> , 2010, 10, 387-93.	0.5	10
52	Mobilisation of mesenchymal cells in cardiac patients: is intense exercise necessary?. <i>British Journal of Sports Medicine</i> , 2009, 43, 221-223.	3.1	8
53	Feeder-free maintenance of hESCs in mesenchymal stem cell-conditioned media: distinct requirements for TGF- $\beta$ 2 and IGF-II. <i>Cell Research</i> , 2009, 19, 698-709.	5.7	69
54	Loss of p53 Induces Tumorigenesis in p21-Deficient Mesenchymal Stem Cells. <i>Neoplasia</i> , 2009, 11, 397-IN9.	2.3	89

#	ARTICLE	IF	CITATIONS
55	Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene. <i>Journal of Experimental Medicine</i> , 2009, 206, 3131-3141.	4.2	109
56	Electron Microscopy Reveals the Presence of Viruses in Mouse Embryonic Fibroblasts But Neither in Human Embryonic Fibroblasts Nor in Human Mesenchymal Cells Used for hESC Maintenance: Toward an Implementation of Microbiological Quality Assurance Program in Stem Cell Banks. <i>Cloning and Stem Cells</i> , 2008, 10, 65-74.	2.6	41
57	Human mesenchymal stem cell transformation is associated with a mesenchymal-epithelial transition. <i>Experimental Cell Research</i> , 2008, 314, 691-698.	1.2	88
58	Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 2552-2565.	1.6	129
59	In vivo site-specific recombination using the $\hat{I}^2$ -rec/sixsystem. <i>BioTechniques</i> , 2008, 45, 69-78.	0.8	7
60	Molecular Characterization of Spontaneous Mesenchymal Stem Cell Transformation. <i>PLoS ONE</i> , 2008, 3, e1398.	1.1	147
61	Cancer Genes Hypermethylated in Human Embryonic Stem Cells. <i>PLoS ONE</i> , 2008, 3, e3294.	1.1	75
62	EARLY-PHASE ADAPTATIONS TO INTRAHOSPITAL TRAINING IN STRENGTH AND FUNCTIONAL MOBILITY OF CHILDREN WITH LEUKEMIA. <i>Journal of Strength and Conditioning Research</i> , 2007, 21, 173-177.	1.0	64
63	Mesenchymal Stem Cells are of Recipient Origin in Pediatric Transplantations Using Umbilical Cord Blood, Peripheral Blood, or Bone Marrow. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 388-392.	0.3	17
64	Human embryonic stem cells: A potential system for modeling infant leukemia harboring MLL-AF4 fusion gene. <i>Drug Discovery Today: Disease Models</i> , 2007, 4, 53-60.	1.2	11
65	Nucleocytoplasmic shuttling of STK16 (PKL12), a Golgi-resident serine/threonine kinase involved in VEGF expression regulation. <i>Experimental Cell Research</i> , 2006, 312, 135-144.	1.2	21
66	Adipose Tissue-Derived Mesenchymal Stem Cells Have In Vivo Immunosuppressive Properties Applicable for the Control of the Graft-Versus-Host Disease. <i>Stem Cells</i> , 2006, 24, 2582-2591.	1.4	649
67	Inducible model for $\hat{A}$ -six-mediated site-specific recombination in mammalian cells. <i>Nucleic Acids Research</i> , 2006, 34, e1-e1.	6.5	9
68	Mobilisation of mesenchymal cells into blood in response to skeletal muscle injury. <i>British Journal of Sports Medicine</i> , 2006, 40, 719-722.	3.1	53
69	Physical activity during treatment in children with leukemia: a pilot study. <i>Applied Physiology, Nutrition and Metabolism</i> , 2006, 31, 407-413.	0.9	67
70	Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors. <i>Cancer Gene Therapy</i> , 2005, 12, 341-349.	2.2	46
71	Intrahospital supervised exercise training: a complementary tool in the therapeutic armamentarium against childhood leukemia. <i>Leukemia</i> , 2005, 19, 1334-1337.	3.3	26
72	Spontaneous Human Adult Stem Cell Transformation. <i>Cancer Research</i> , 2005, 65, 3035-3039.	0.4	997

#	ARTICLE	IF	CITATIONS
73	In Vitro and In Vivo Immunomodulatory Effects of Mesenchymal Stem Cells from Adipose Tissue.. Blood, 2005, 106, 3098-3098.	0.6	3
74	Absence of hematopoiesis from transplanted olfactory bulb neural stem cells. European Journal of Neuroscience, 2004, 19, 505-512.	1.2	40
75	Dedifferentiated adult articular chondrocytes: a population of human multipotent primitive cells. Experimental Cell Research, 2004, 297, 313-328.	1.2	75
76	Purging of leukemia-contaminated bone marrow grafts using suicide adenoviral vectors: an in vivo murine experimental model. Gene Therapy, 2003, 10, 1328-1335.	2.3	7
77	Efficient and nontoxic adenoviral purging method for autologous transplantation in breast cancer patients. Cancer Research, 2002, 62, 5013-8.	0.4	12
78	Selective Transduction of Murine Myelomonocytic Leukemia Cells (WEHI-3B) with Regular and RGD-Adenoviral Vectors. Molecular Therapy, 2001, 3, 70-77.	3.7	22
79	Transplantation of syngenic bone marrow contaminated with NGFr-marked WEHI-3B cells: an improved model of leukemia relapse in mice. Leukemia, 2000, 14, 457-465.	3.3	6
80	SOX2 Expression and Transcriptional Activity Identifies a Subpopulation of Cancer Stem Cells in Sarcoma with Prognostic Implications. SSRN Electronic Journal, 0, , .	0.4	3